Impax announces data from IPX066 Phase III study on Parkinson's

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28. IPX066 is an investigational, patented extended release capsule formulation of carbidopa-levodopa (CD-LD) intended for the treatment of idiopathic Parkinson's disease. IPX066 is being developed in collaboration with GlaxoSmithKline (GSK) for territories countries outside the U.S. and Taiwan.

The presentation information is as follows:

ASCEND-PD Presentation
Title: Comparison of IPX066, a Novel Investigational Carbidopa-Levodopa (CD-LD) Extended-Release Formulation, and CD-LD-Entacapone (CLE) in Advanced Parkinson's Disease (ASCEND-PD Trial)

Date: April 24, 2012
Time: 2:00 p.m.
Location: New Orleans Ernest N. Memorial Convention Center
Scientific Session: S02 (Treatment of Parkinson's Disease)
Abstract Number: S02.005


Impax Pharmaceuticals


  1. Ruthie Cusick Ruthie Cusick United States says:

    My husband has early stage parkinsons and is currently taking Requip XL. Is the IPX066 a better type of levadopa and can it be used for early stage parkinsons?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
‘Sting’ protein’s response to clean up damaged brain cells may accelerate Parkinson’s disease progression